がん遺伝子治療市場レポート：2030年までの動向、予測、競合分析

がん遺伝子治療の動向と予測

世界のがん遺伝子治療市場は、2024年から2030年までのCAGRが17.4%で、2030年までに推定74億米ドルに達すると予想されています。この市場の主な促進要因は、遺伝子治療に対する需要の増加、がん治療と皮膚病における技術開発の進展、がん罹患率の増加です。世界のがん遺伝子治療市場は、病院、バイオ製薬会社、研究機関の各市場におけるビジネスチャンスにより、将来が有望視されています。

がん遺伝子治療市場の洞察

Lucintel社は、がんの増殖を抑えるための研究開発活動が活発化していることから、予測期間中、遺伝子誘導免疫療法が最大の市場規模を維持すると予測しています。

この市場の中では、がんの罹患率の増加と、がん治療レジメンを設計するための主要なバイオ製薬企業による要素遺伝子治療ソリューションの採用増加により、バイオ製薬企業が最大セグメントであり続けると思われます。

北米は、政府機関による革新的治療薬への研究資金提供の増加や、同地域で急増するがん症例に対処するための新規治療薬に対する需要の高まりにより、予測期間中も最大地域であり続けると思われます。

本レポートでは、以下の11の主要な質問に回答している：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のがん遺伝子治療市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のがん遺伝子治療市場の動向（2018～2023年）と予測（2024～2030年）
• 治療別の世界のがん遺伝子治療市場
  • 腫瘍溶解性ウイルス療法
  • 遺伝子誘導免疫療法
  • 遺伝子導入
  • その他
• 適応別の世界のがん遺伝子治療市場
  • 乳がん
  • 卵巣がん
  • 肝臓がん
  • 膵臓がん
  • 肺がん
  • その他
• 最終用途別の世界のがん遺伝子治療市場
  • 病院
  • バイオ医薬品企業
  • 調査機関
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のがん遺伝子治療市場
• 北米のがん遺伝子治療市場
• 欧州のがん遺伝子治療市場
• アジア太平洋がん遺伝子治療市場
• その他地域がん遺伝子治療市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 治療別の世界のがん遺伝子治療市場の成長機会
  • 適応別の世界のがん遺伝子治療市場の成長機会
  • 最終用途別の世界のがん遺伝子治療市場の成長機会
  • 地域別の世界のがん遺伝子治療市場の成長機会
• 世界のがん遺伝子治療市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のがん遺伝子治療市場の能力拡大
  • 世界のがん遺伝子治療市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Abeona Therapeutics
• Asklepios BioPharmaceutical
• Altor Bioscience
• Bluebird bio
• BioCancell
• Celgene
• Elevate Bio
• GlaxoSmithKline
• Genelux
• GenVec

Cancer Gene Therapy Trends and Forecast

The future of the global cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets. The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030 with a CAGR of 17.4% from 2024 to 2030. The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

A more than 150-page report is developed to help in your business decisions.

Cancer Gene Therapy by Segment

The study includes a forecast for the global cancer gene therapy by therapy, indication, end use, and region.

Cancer Gene Therapy Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

• Oncolytic Virotherapy
• Gene Induced Immunotherapy
• Gene Transfer
• Others

Cancer Gene Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

• Breast Cancer
• Ovarian Cancer
• Liver Cancer
• Pancreatic Cancer
• Lung Cancer
• Others

Cancer Gene Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Biopharmaceutical Companies
• Research Institutes
• Others

Cancer Gene Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cancer Gene Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer gene therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer gene therapy companies profiled in this report include-

• Abeona Therapeutics
• Asklepios Biopharmaceutical
• Altor Bioscience
• Bluebird Bio
• Biocancell
• Celgene
• Elevate Bio
• Glaxosmithkline
• Genelux
• Genvec

Cancer Gene Therapy Market Insights

Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Within this market, biopharmaceutical companies will remain the largest segment due to increasing prevelance of cancer and growing adoption of elemental gene therapy solutions by major biopharmaceutical companies for designing cancer treatment regimens.

North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Features of the Global Cancer Gene Therapy Market

Market Size Estimates: Cancer gene therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer gene therapy market size by therapy, indication, end use, and region in terms of value ($B).

Regional Analysis: Cancer gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapies, indications, end uses, and regions for the cancer gene therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer gene therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer gene therapy market size?

Answer: The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030.

Q.2 What is the growth forecast for cancer gene therapy market?

Answer: The global cancer gene therapy market is expected to grow with a CAGR of 17.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer gene therapy market?

Answer: The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

Q4. What are the major segments for cancer gene therapy market?

Answer: The future of the cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets.

Q5. Who are the key cancer gene therapy market companies?

Answer: Some of the key cancer gene therapy companies are as follows:

• Abeona Therapeutics
• Asklepios Biopharmaceutical
• Altor Bioscience
• Bluebird Bio
• Biocancell
• Celgene
• Elevate Bio
• Glaxosmithkline
• Genelux
• Genvec

Q6. Which cancer gene therapy market segment will be the largest in future?

Answer: Lucintel forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Q7. In cancer gene therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer gene therapy market by therapy (oncolytic virotherapy, gene induced immunotherapy, gene transfer, and others), indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and others), end use (hospitals, biopharmaceutical companies, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Gene Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Cancer Gene Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Cancer Gene Therapy Market by Therapy
  • 3.3.1: Oncolytic Virotherapy
  • 3.3.2: Gene Induced Immunotherapy
  • 3.3.3: Gene Transfer
  • 3.3.4: Others
• 3.4: Global Cancer Gene Therapy Market by Indication
  • 3.4.1: Breast Cancer
  • 3.4.2: Ovarian Cancer
  • 3.4.3: Liver Cancer
  • 3.4.4: Pancreatic Cancer
  • 3.4.5: Lung Cancer
  • 3.4.6: Others
• 3.5: Global Cancer Gene Therapy Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Biopharmaceutical companies
  • 3.5.3: Research Institutes
  • 3.5.4: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Cancer Gene Therapy Market by Region
• 4.2: North American Cancer Gene Therapy Market
  • 4.2.2: North American Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
• 4.3: European Cancer Gene Therapy Market
  • 4.3.1: European Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
  • 4.3.2: European Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
• 4.4: APAC Cancer Gene Therapy Market
  • 4.4.1: APAC Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
  • 4.4.2: APAC Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
• 4.5: ROW Cancer Gene Therapy Market
  • 4.5.1: ROW Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
  • 4.5.2: ROW Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cancer Gene Therapy Market by Therapy
  • 6.1.2: Growth Opportunities for the Global Cancer Gene Therapy Market by Indication
  • 6.1.3: Growth Opportunities for the Global Cancer Gene Therapy Market by End Use
  • 6.1.4: Growth Opportunities for the Global Cancer Gene Therapy Market by Region
• 6.2: Emerging Trends in the Global Cancer Gene Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cancer Gene Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Gene Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abeona Therapeutics
• 7.2: Asklepios BioPharmaceutical
• 7.3: Altor Bioscience
• 7.4: Bluebird bio
• 7.5: BioCancell
• 7.6: Celgene
• 7.7: Elevate Bio
• 7.8: GlaxoSmithKline
• 7.9: Genelux
• 7.10: GenVec